Barinthus Biotherapeutics (BRNS) Free Cash Flow (2020 - 2026)

Barinthus Biotherapeutics has reported Free Cash Flow for 7 years, with the latest figure at -$3.4 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 77.42% year-over-year to -$3.4 million; the trailing twelve-month figure through Mar 2026 stood at -$36.5 million (down 11.86% YoY), and the FY2025 full-year result was -$48.0 million, down 60.95% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$3.4 million, up from -$4.2 million in the prior quarter.
• The five-year high for Free Cash Flow was $12.8 million in Q4 2024, with the low at -$18.3 million in Q3 2024.
• Historically, Free Cash Flow has averaged -$9.0 million across 5 years, with a median of -$11.9 million in 2022.
• Annual changes were most pronounced in 2022 — Free Cash Flow surged 394.91% — and 2023, when it slumped 301.85%.
• Barinthus Biotherapeutics' Free Cash Flow stood at -$11.9 million in 2022, then slipped by 18.4% to -$14.1 million in 2023, then jumped by 190.68% to $12.8 million in 2024, then sank by 133.12% to -$4.2 million in 2025, then gained by 20.65% to -$3.4 million in 2026.
• The last three Free Cash Flow figures came in at -$3.4 million (Q1 2026), -$4.2 million (Q4 2025), and -$10.7 million (Q3 2025), per Business Quant data.